StreetInsider.com News Articles

Top Biotech Stock: Guggenheim Names Surrozen as Best Pick

Thu, 15 Oct 2026 13:57:12 -0400

Investing.com -- Guggenheim Securities has identified Surrozen, Inc. as its top pick in the biotechnology sector, assigning a Buy rating with a price target of $42.00. The firm hosted management from Surrozen to discuss recent developments in retinal vascular disease treatments and the company's clinical pipeline.

Guggenheim views Surrozen as significantly undervalued at approximately $730 million market capitalization. The investment thesis centers on the company's lead drug candidate, SZN-8141, which combines Wnt agonism with anti-VEGF therapy in a single molecule. Management positions this drug as a premium first-line biologic benchmarked against Vabysmo.

1. Surrozen, Inc. (SRZN)

Guggenheim's top biotechnology pick

Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: Boxer Capital Management, LLC

Wed, 07 Oct 2026 19:07:00 -0400

si-local-file:///var/storage/secattach/20261007/27162217.html

Form 8-K Surrozen, Inc./DE For: Oct 02

Fri, 02 Oct 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20261002/27139057.html

Surrozen gets FDA IND clearance for DME drug, expects $95.1M funding

Fri, 02 Oct 2026 08:02:59 -0400

Surrozen, Inc. (Nasdaq: SRZN) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for SZN-8141, a bifunctional antibody being developed as an intravitreal injection for the treatment of diabetic macular edema (DME).

The company expects to dose the first patient in the DUET Phase 1b/2a clinical study in the fourth quarter of 2026, with initial data anticipated in the second half of 2027. The trial will evaluate the safety, tolerability, and early clinical activity of SZN-8141 in DME patients. Part 2 of the study is expected to compare two dose levels of SZN-8141 against Vabysmo

Surrozen gets FDA IND clearance for DME drug, expects $95.1M funding

Fri, 02 Oct 2026 08:02:59 -0400

Surrozen gets FDA IND clearance for DME drug, expects $95.1M funding

Fri, 02 Oct 2026 08:02:59 -0400

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

Fri, 02 Oct 2026 08:00:00 -0400

First patient expected to be dosed in the DUET study in the fourth quarter of 2026

Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

Fri, 02 Oct 2026 08:00:00 -0400

First patient expected to be dosed in the DUET study in the fourth quarter of 2026

Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds

Form SCHEDULE 13G Surrozen, Inc./DE Filed by: Commodore Capital LP

Thu, 01 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27136972.html

Surrozen Inc. (SRZN) PT Raised to $54 at H.C. Wainwright

Fri, 25 Sep 2026 06:49:11 -0400

(Updated - September 25, 2026 6:49 AM EDT)

H.C. Wainwright analyst Matthew Caufield raised the price target on Surrozen Inc. (NASDAQ: SRZN) to $54.00 (from $44.00) while maintaining a Buy rating.

The analyst commented: "In light of Merck announcing initial positive topline from its pivotal Phase 2b/3 BRUNELLO trial in diabetic macular edema (DME) adults, we believe there is merit to the read-through for SRZN’s own SZN-8141, expected to enter the clinic by YE26 in DME patients. We note Merck’s asset, remigromig, is a tri-specific agonist of the novel Wingless-related integration site (Wnt) pathway implicated in the repair and maintenance of the

Surrozen Inc. (SRZN) PT Raised to $54 at H.C. Wainwright

Fri, 25 Sep 2026 06:49:11 -0400

(Updated - September 25, 2026 6:49 AM EDT)

H.C. Wainwright analyst Matthew Caufield raised the price target on Surrozen Inc. (NASDAQ: SRZN) to $54.00 (from $44.00) while maintaining a Buy rating.

William Blair Starts Surrozen Inc. (SRZN) at Outperform

Thu, 20 Aug 2026 05:57:30 -0400

(Updated - August 20, 2026 5:57 AM EDT)

William Blair analyst Lachlan Hanbury-Brown initiates coverage on Surrozen Inc. (NASDAQ: SRZN) with a Outperform rating.

The analyst comments "We are initiating coverage of Surrozen with an Outperform rating and fair value estimate of $51 per share. Surrozen is a biotechnology company developing multispecific antibodies that leverage Wnt agonism—and specifically FZD4 agonism—for the treatment of serious retinal diseases. While Wnt agonism is a relatively new mechanism in vascular retinopathies, Phase I/II data with Merck/EyeBio’s MK-3000 (remigromig; formerly Restoret) demonstrated clinical proof-of-concept, and we expect the first Phase III readout in second half 2026. Surrozen

William Blair Starts Surrozen Inc. (SRZN) at Outperform

Thu, 20 Aug 2026 05:57:30 -0400

(Updated - August 20, 2026 5:57 AM EDT)

William Blair analyst Lachlan Hanbury-Brown initiates coverage on Surrozen Inc. (NASDAQ: SRZN) with a Outperform rating.

Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: BRAIDWELL LP

Fri, 14 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26930622.html

Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: BRAIDWELL LP

Fri, 14 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26930622.html

Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: Boxer Capital Management, LLC

Fri, 14 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26930247.html

Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: Boxer Capital Management, LLC

Fri, 14 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26930247.html

Form SCHEDULE 13G Surrozen, Inc./DE Filed by: STEMPOINT CAPITAL LP

Fri, 14 Aug 2026 12:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26927524.html

Form SCHEDULE 13G Surrozen, Inc./DE Filed by: STEMPOINT CAPITAL LP

Fri, 14 Aug 2026 12:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26927524.html

Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: 5AM Partners VII, LLC

Tue, 11 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260811/26906147.html

Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: 5AM Partners VII, LLC

Tue, 11 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260811/26906147.html

H.C. Wainwright Reiterates Buy Rating on Surrozen Inc. (SRZN)

Mon, 10 Aug 2026 06:52:34 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $44.00 price target on Surrozen Inc. (NASDAQ: SRZN).

The analyst commented: "We are encouraged to see greater granularity around the next clinical steps for lead novel bifunctional Wnt/ anti-VEGF antibody SZN-8141 entering the clinic in the near-term, for the treatment of diabetic macular edema (DME) patients. More specifically, the planned IND submission for SZN-8141 in DME is anticipated by the end of 3Q26, refined from previous estimates of 2H26, with the Phase 1b/2a DUET trial for SZN-8141 in DME patients expected to initiate by year-end 2026. Pending successful trial initiation and

Form 25-NSE Surrozen, Inc./DE Filed by: Nasdaq Stock Market LLC

Fri, 07 Aug 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26892057.html

Form 25-NSE Surrozen, Inc./DE Filed by: Nasdaq Stock Market LLC

Fri, 07 Aug 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26892057.html

Form 10-Q Surrozen, Inc./DE For: Jun 30

Thu, 06 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260806/26884567.html